Novel Target for ALS Treatment Identified

An inflammatory monocyte population serves as a potential therapeutic target for amyotrophic lateral sclerosis (ALS).

Although the mechanism of ALS is not completely understood, inflammation is believed to play a role in the disease process. A recent study by Howard Weiner and colleagues at Harvard Medical School and Tufts School of Medicine investigated the role of inflammation in a mouse model of ALS. Weiner and colleagues found that the recruitment of activated immune cells known as monocytes into the spinal cord correlated with increased CNS cell death, and this recruitment was mediated by high expression of the chemoattractant protein CCL2 by resident spinal cord-derived immune cells.

Amyotrophic Lateral Sclerosis (ALS)-Lou Gehrig's disease: Symptoms, Diagnosis, Treatment
Find out more about the degenerative disease- Amyotrophic lateral sclerosis.

Antibody-mediated depletion of the monocyte population reduced cellular recruitment to the spinal cord, decreased CNS cell death, and extended survival time in the mice. The analogous monocyte population in humans with ALS exhibited a similar inflammatory signature to the ALS model mice, suggesting that this cell population could serve as a marker of disease progression in human ALS patients.

Source-Eurekalert

Know your immune system
Immune system is the first line of defense against Viruses, bacteria, fungi, worms and other parasites, which enter the body through the skin, nose, mouth or other openings of the body, cause infectious diseases

Amyotrophic Lateral Sclerosis - New Findings
Pluripotent stem cells derived from patients with ALS sheds light on how reduced levels of a specific protein may play a key role in causing inherited ALS.

Lithium Doesn't Delay Progression of Amyotrophic Lateral Sclerosis
Lithium doesn't delay progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, and shouldn't be used to treat patients with the disease, researchers say.